NCM – Real vaqt narxi. Valyuta: USD
3.56
-0.55 (-13.38%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
3.80
+0.24 (6.75%)
Bozordan keyin: Mar 27, 2026, 6:10 PM EDT
Insight Molecular Diagnostics Inc. Qo'shma Shtatlar va xalqaro miqyosda aniq diagnostika kompaniyasi sifatida faoliyat yuritadi. Kompaniya laboratoriya tomonidan ishlab chiqilgan testlar, tadqiqotlar uchun to'plamlar va klinik testlar to'plamlarini ishlab chiqadi va tijoratlashtiradi. U saratonni bir marta davolashdan keyin erta rivojlanishni aniqlaydigan qonga asoslangan monitoring vositasi DetermaCNI; va immunoterapiyaga javobni bashorat qilish uchun o'simta mikro-muhitini baholaydigan gen ekspressiya testi DetermaIOni ishlab chiqmoqda. Kompaniya, shuningdek, buyrak transplantatsiyasi uchun donor-hosil bo'lgan hujayrasiz DNK kontsentratsiyasini miqdorini aniqlaydigan qonga asoslangan transplantatsiya monitoring testi VitaGraft Kidney; jigar transplantatsiyasi uchun donor-hosil bo'lgan hujayrasiz DNK kontsentratsiyasini miqdorini aniqlaydigan qonga asoslangan transplantatsiya monitoring testi VitaGraft Liver; va 48 ta oldindan belgilangan SNPlardan foydalangan holda dd-cfDNA kontsentratsiyasini o'lchash uchun tomchi raqamli PCR texnologiyasidan foydalanadigan dd-cfDNA testi GraftAssureni taklif qiladi. Bundan tashqari, u biomarkerlarni kashf qilish, tahlilni loyihalash va ishlab chiqish, klinik sinovlarni qo'llab-quvvatlash va turli biomarker testlari uchun test xizmatlarini taqdim etadi. Kompaniya Bio-Rad Laboratories, Inc. bilan Bio-Radning ddPCR asbob-uskunalari va reagentlaridan foydalangan holda tadqiqotlar va in vitro diagnostika transplantatsiya mahsulotlarini ishlab chiqish va tijoratlashtirish bo'yicha hamkorlik shartnomasiga ega. Insight Molecular Diagnostics Inc. ilgari OncoCyte Corporation nomi bilan tanilgan va 2025 yil iyun oyida Insight Molecular Diagnostics Inc.ga nomini o'zgartirgan. Insight Molecular Diagnostics Inc. 2009 yilda tashkil etilgan va Neshvill, Tennessi shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. |
| Dr. Paul R. Billings FACP, M.D., Ph.D. | Consulting Chief Medical Officer |
| Mr. James Liu | VP of Accounting, Treasurer, Controller & Principal Accounting Officer |
| Mr. Joshua Riggs | President, CEO & Director |
| Mr. Peter Hong | VP, General Counsel & Secretary |
| Mr. Steven Tahmooressi | Vice President of Marketing |
| Mr. Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Ms. Andrea Susan James | Chief Financial Officer |
| Ms. Sandra O'Donald | Senior Vice President of Business Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-11-10 | 8-K | form8-k.htm |
| 2025-10-02 | 8-K | form8-k.htm |
| 2025-09-19 | 8-K | form8-k.htm |
| 2025-08-18 | S-8 | forms-8.htm |
| 2025-08-11 | 10-Q | imdx-20250630.htm |
| 2025-07-02 | 8-K | form8-k.htm |
| 2025-06-17 | 8-K | form8-k.htm |
| 2025-05-12 | 10-Q | ocx-20250331.htm |
| 2025-04-17 | 8-K | form8-k.htm |
| 2025-04-04 | CORRESP | filename1.htm |